Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.64 |
| ▸ | NOS1 | P29475 | 5/20 | 0.64 |
| ▸ | NOS3 | P29474 | 4/20 | 0.64 |
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | ARG2 | P78540 | 4/20 | 0.48 |
| ▸ | ARG1 | P05089 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BHMT | Q93088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27932086 | 0.87 | NOS2 (0.62) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL12492046 | 0.87 | NOS2 (0.67) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL881063 | 0.84 | NOS2 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL1527409 | 0.84 | NOS2 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL358975 | 0.84 | NOS2 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL18460231 | 0.84 | NOS2 (0.90) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL26646413 | 0.84 | NOS2 (0.90) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL18883517 | 0.84 | NOS1 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL26646410 | 0.84 | NOS2 (0.90) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL920513 | 0.82 | NOS2 (0.56) | NOS2NOS1NOS3GSRARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250331-A1 | ANTI-AGE ANTIBODIES FOR TREATING NEURODEGENERATIVE DISORDERS | SIWA CORP (US) | 2025-08-07 | — | — | US | disclosed |
| US-12226465-B2 | Humanized monoclonal advanced glycation end-product antibody | SIWA CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4388016-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | Siwa Corporation (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024102157-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES AND DIABETIC COMPLICATIONS | SIWA CORPORATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11958900-B2 | Anti-age antibodies for treating neurodegenerative disorders | SIWA CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| US-11872269-B2 | Method and composition for treating sarcopenia | SIWA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873345-B2 | Product and method for treating sarcopenia | SIWA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240000930-A1 | METHODS AND COMPOSITIONS FOR TREATING KIDNEY DISEASES | SIWA CORP (US) | 2024-01-04 | — | — | US | disclosed |
| US-11833202-B2 | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) | SIWA CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230295282-A1 | HUMANIZED MONOCLONAL ADVANCED GLYCATION END-PRODUCT ANTIBODY | SIWA CORP (US) | 2023-09-21 | — | — | US | disclosed |
| US-20180298087-A1 | HUMANIZED MONOCLONAL ADVANCED GLYCATION END-PRODUCT ANTIBODY | SIWA CORP (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3362483-A1 | ANTI-AGE ANTIBODIES AND METHODS OF USE THEREOF | Siwa Corporation (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-3337829-A1 | METHOD AND COMPOSITION FOR TREATING CANCER, KILLING METASTATIC CANCER CELLS AND PREVENTING CANCER METASTASIS USING ANTIBODY TO ADVANCED GLYCATION END PRODUCTS (AGE) | Siwa Corporation (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9993535-B2 | Method and composition for treating sarcopenia | SIWA CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2017222535-A1 | VACCINES FOR USE IN TREATING VARIOUS DISEASES AND DISORDERS | SIWA CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017181116-A1 | ANTI-AGE ANTIBODIES FOR TREATING NEURODEGENERATIVE DISORDERS | SIWA CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017143073-A1 | METHOD AND COMPOSITION FOR TREATING CANCER, KILLING METASTATIC CANCER CELLS AND PREVENTING CANCER METASTASIS USING ANTIBODY TO ADVANCED GLYCATION END PRODUCTS (AGE) | SIWA CORPORATION (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017065837-A1 | ANTI-AGE ANTIBODIES AND METHODS OF USE THEREOF | SIWA CORPORATION (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20160215043-A1 | PRODUCT AND METHOD FOR TREATING SARCOPENIA | SIWA CORPORATION | 2016-07-28 | — | — | US | disclosed |
| US-20160175413-A1 | METHOD AND COMPOSITION FOR TREATING SARCOPENIA | SIWA CORPORATION | 2016-06-23 | — | — | US | disclosed |